Study ID,Study,Experiment Name,Experiment Notes,Strain Ont ID,Strain,Sex,Age,# of Animals,Sample Notes,Clinical Measurement Ont ID,Phenotype,Formula,Clinical Measurement Notes,Average Type,Value,Units,SEM,SD,Method Ont ID,Method,Method Site,Method Duration,Method Notes,Post Insult Type,Post Insult Time Value,Post Insult Time Unit,Conditions,Record ID,Condition 1,Condition 2 3097,"Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.",platelet size trait,,RS:0001789,BDIX/CrCrl,male,71 days,10,,CMO:0001350,platelet distribution width,,,,8.7,fl,0.1581,0.5,MMO:0000174,automated hematology analysis,,0.0,,,,,DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) ,107882,DHD/K12/TRb cells (1.5 X 10E6) ,vehicle control condition (1 ml) 3097,"Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.",platelet size trait,,RS:0001789,BDIX/CrCrl,male,92 days,10,,CMO:0001350,platelet distribution width,,,,8.6,fl,0.0316,0.1,MMO:0000174,automated hematology analysis,,0.0,,,,,DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) ,107884,DHD/K12/TRb cells (1.5 X 10E6) ,vehicle control condition (1 ml)